Although the expression of GLP-1R in liver tissue is controversial, GLP-1RAs have been shown to act as regulatory pathways affecting metabolic disorders
4 Efforts to extend the life of native GLP-1 led to the development of human GLP-1 analogs liraglutide, albiglutide, dulaglutide, and semaglutide
At the heart of this transformation are GLP-1-based therapies, a class of drugs that has rapidly moved from diabetes treatment into the center stage of obesity care and beyond
These two compounds target fat loss through completely separate biological pathways, which means they complement rather than compete with each other
In Phase 3 trials, retatrutide 12 mg achieved 28.7% body weight reduction at 68 weeks, while mazdutide 9 mg achieved 20.1% at 60 weeks
We follow personalised methods for everyone according to their body type, current weight, and lifestyle habits